A phase I clinical trial to evaluate the tolerability and safety of an allogeneic iPSC-derived iNKT cell and α-GalCer-pulsed autologous DC combination therapy for patients with recurrent and advanced head and neck cancer: A study protocol
Fig 2
The study outline, including all study visits and timeline.
Abbreviations: DC/Gal: dendritic cells pulsed with a-Galactosylceramide; DLT: dose limiting toxicity; iPSC-iNKT: induced pluripotent stem cell-derived invariant natural killer T.